PureTech Health (LON:PRTC) Hits New 1-Year Low – Here’s What Happened

PureTech Health plc (LON:PRTC) shares hit a new 52-week low during trading on Thursday . The company traded as low as GBX 123.20 ($1.59) and last traded at GBX 135.40 ($1.75), with a volume of 26766676 shares trading hands. The stock had previously closed at GBX 127.20 ($1.65).

Analysts Set New Price Targets

Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 455 ($5.89) price objective on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Stock Up 9.5 %

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The firm has a market cap of £442.16 million, a P/E ratio of -6.04 and a beta of 1.02. The firm’s 50-day moving average price is GBX 139.75 and its 200 day moving average price is GBX 149.81.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.